Checkpoint Inhibitor Generated by Synthetic DNA <em>in Vivo</em>

The cancer immunotherapy toolbox may one day make room for a new tool, the DNA-encoded monoclonal antibody (DMAb). Like conventional monoclonal antibodies, DMAbs bind to cancer checkpoint molecules, thereby releasing the brakes on immune cell activity. Unlike conventional monoclonal antibodies, DMAbs are expressed in vivo rather than being painstakingly manufactured, stored, transported, and finally administered. Moreover, in mice, DMAbs are expressed persistently, suggesting that DMAbs could sp